Vertex Pharmaceuticals Expands Beyond Cystic Fibrosis at Cantor Conference
At the Cantor Global Healthcare Conference, Vertex Pharmaceuticals outlined a strategy to expand beyond cystic fibrosis through recent acquisitions and pipeline advancements. The company highlighted its acquisition of Crinetics, which added PALSONIFY for acromegaly and late-stage candidate atumelnant for congenital adrenal hyperplasia—both with potential peak sales estimated at $5 billion combined. Vertex also emphasized progress in its renal portfolio, including the November 30 FDA decision date for povetacicept in IgA nephropathy. The company is advancing this drug into other indications like primary membranous nephropathy and myasthenia gravis. Additionally, Vertex expects Phase II data on inaxaplin before year-end and a Phase III interim analysis by early 2027. The firm also noted growth from JOURNAVX as insurance coverage expands and its sales force scales up, aiming to triple prescriptions in 2026 compared to 2025. Vertex is nearing completion of enrollment for suzetrigine’s Phase III trials on diabetic peripheral neuropathy.
Topics: commercial growth Crinetics acquisition drug pipeline FDA decisions Vertex Pharmaceuticals